The mean of analysts' price targets for Auna S.A. (AUNA) points to a 39.3% upside in the stock.
Here is how Auna S.A. (AUNA) and BioNTech SE Sponsored ADR (BNTX) have performed compared to their sector so far this year.
Auna is a leading player in the Spanish-speaking Latin America medical industry, focusing particularly on high-complexity diseases, such as cancer. Most SSLA have a highly fragmented and underserved healthcare market, and populations are becoming elderly, demanding more and better services. AUNA stock has been impacted negatively following its IPO process, as local institutional players such as pension funds overbought the stock and had to sell due to regulatory limits.
MONTERREY, Mexico--(BUSINESS WIRE)--Auna S.A. (NYSE: AUNA) (“Auna” or the “Company”), a Latin American healthcare company with operations in Mexico, Peru and Colombia, announced today the closing of a private placement of USD 57,826,321 aggregate principal amount of its 10.000% Senior Secured Notes due 2029 (the "Additional 2029 Notes"). The proceeds from the Additional 2029 Notes were used to fully redeem the USD 57,826,321 in aggregate principal amount outstanding of its 6.500% Senior Secured.